FI956203A - Lisääntyneen biologisen aktiivisuuden omaava katkaistu keratinosyyttika sivutekijä (KGF) - Google Patents
Lisääntyneen biologisen aktiivisuuden omaava katkaistu keratinosyyttika sivutekijä (KGF) Download PDFInfo
- Publication number
- FI956203A FI956203A FI956203A FI956203A FI956203A FI 956203 A FI956203 A FI 956203A FI 956203 A FI956203 A FI 956203A FI 956203 A FI956203 A FI 956203A FI 956203 A FI956203 A FI 956203A
- Authority
- FI
- Finland
- Prior art keywords
- kgf
- biological activity
- increased biological
- side factor
- keratinocyte
- Prior art date
Links
- 230000004071 biological effect Effects 0.000 title 1
- 210000002510 keratinocyte Anatomy 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000057239 human FGF7 Human genes 0.000 abstract 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 abstract 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8642793A | 1993-06-29 | 1993-06-29 | |
| PCT/US1994/004694 WO1995001434A1 (en) | 1993-06-29 | 1994-04-28 | A truncated keratinocyte growth factor (kgf) having increased biological activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI956203A0 FI956203A0 (fi) | 1995-12-22 |
| FI956203A true FI956203A (fi) | 1996-02-07 |
Family
ID=22198501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI956203A FI956203A (fi) | 1993-06-29 | 1995-12-22 | Lisääntyneen biologisen aktiivisuuden omaava katkaistu keratinosyyttika sivutekijä (KGF) |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US5677278A (sk) |
| EP (2) | EP1493812A3 (sk) |
| JP (4) | JP3570516B2 (sk) |
| KR (1) | KR960703433A (sk) |
| CN (1) | CN1129955A (sk) |
| AT (1) | ATE278777T1 (sk) |
| AU (1) | AU681405B2 (sk) |
| BG (1) | BG100236A (sk) |
| BR (1) | BR9407035A (sk) |
| CA (1) | CA2166278A1 (sk) |
| CZ (1) | CZ343795A3 (sk) |
| DE (2) | DE122006000005I2 (sk) |
| DK (1) | DK0706563T3 (sk) |
| ES (1) | ES2227527T3 (sk) |
| FI (1) | FI956203A (sk) |
| FR (1) | FR06C0004I2 (sk) |
| HU (1) | HUT73453A (sk) |
| LU (1) | LU91215I2 (sk) |
| NL (1) | NL300217I2 (sk) |
| NO (1) | NO955189L (sk) |
| NZ (1) | NZ266622A (sk) |
| PL (1) | PL312257A1 (sk) |
| PT (1) | PT706563E (sk) |
| SK (1) | SK153295A3 (sk) |
| WO (1) | WO1995001434A1 (sk) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990008771A1 (en) | 1989-01-31 | 1990-08-09 | Rubin Jeffrey S | Dna encoding a growth factor specific for epithelial cells |
| US7026291B1 (en) | 1989-01-31 | 2006-04-11 | The United States Of America As Represented By The Department Of Health And Human Services | Epithelial cell specific growth factor, keratinocyte growth factor (KGF) |
| US5965530A (en) * | 1993-03-26 | 1999-10-12 | Amgen Inc. | Therapeutic uses of keratinocyte growth factor |
| WO1995001434A1 (en) * | 1993-06-29 | 1995-01-12 | Chiron Corporation | A truncated keratinocyte growth factor (kgf) having increased biological activity |
| US7084119B2 (en) * | 1993-06-29 | 2006-08-01 | Chiron Corporation | Truncated keratinocyte growth factor (KGF) having increased biological activity |
| CN1168678A (zh) * | 1994-10-13 | 1997-12-24 | 安姆根有限公司 | 用kgf治疗糖尿病的方法 |
| AU745815B2 (en) * | 1994-10-13 | 2002-04-11 | Biovitrum Ab (Publ) | Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using |
| US6008328A (en) * | 1994-10-13 | 1999-12-28 | Amgen Inc. | Method for purifying keratinocyte growth factors |
| DE69530599T2 (de) * | 1994-10-13 | 2003-11-13 | Amgen Inc., Thousand Oaks | Methode zur reinigung von keratinocyten-wachstumsfaktoren |
| US6077692A (en) | 1995-02-14 | 2000-06-20 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| US6693077B1 (en) | 1995-02-14 | 2004-02-17 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| US7232667B2 (en) | 1995-02-14 | 2007-06-19 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 polynucleotides |
| PT1486565E (pt) * | 1995-10-11 | 2008-02-28 | Novartis Vaccines & Diagnostic | Combinação de pdgf, kgf, igf e igfbp para cicatrização de ferimentos |
| US6692961B1 (en) | 1996-10-11 | 2004-02-17 | Invitrogen Corporation | Defined systems for epithelial cell culture and use thereof |
| SI0935652T1 (en) * | 1996-10-15 | 2004-06-30 | Amgen Inc. | Keratinocyte growth factor-2 products |
| US20030144202A1 (en) * | 1996-10-15 | 2003-07-31 | Amgen Inc. | Uses of keratinocyte growth factor-2 |
| DE69728415T2 (de) * | 1996-10-15 | 2004-08-12 | Amgen Inc., Thousand Oaks | Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2) |
| US6743422B1 (en) | 1996-10-15 | 2004-06-01 | Amgen, Inc. | Keratinocyte growth factor-2 products |
| JP2002513294A (ja) * | 1997-06-19 | 2002-05-08 | ジェネティックス・インスチチュート・インコーポレーテッド | 分泌蛋白およびそれらをコードするポリヌクレオチド |
| US20080233086A1 (en) * | 1997-09-05 | 2008-09-25 | Canbiocin Inc. | Expression Vectors for Treating Bacterial Infections |
| EP1041996A4 (en) * | 1997-12-22 | 2003-05-14 | Human Genome Sciences Inc | KERATINOCYTE GROWTH FACTOR-2 FORMULATIONS |
| US6869927B1 (en) | 1997-12-22 | 2005-03-22 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
| CA2320515A1 (en) * | 1998-02-13 | 1999-08-19 | Human Genome Sciences, Inc. | Therapeutic uses of keratinocyte growth factor-2 |
| DE19934510B4 (de) * | 1999-07-22 | 2009-04-16 | Vermicon Ag | Verfahren zum Nachweis von Mikroorganismen |
| AU2039501A (en) | 1999-10-15 | 2001-04-23 | Rockefeller University, The | System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae |
| DE10024334B4 (de) * | 2000-05-17 | 2006-06-01 | Medigene Ag | Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat |
| AU2002236477A1 (en) | 2000-11-21 | 2002-06-03 | The Texas A & M University System | Fgf-affinity chromatography |
| AU2002309473A1 (en) * | 2001-01-08 | 2002-10-08 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| WO2002069232A2 (en) | 2001-02-19 | 2002-09-06 | Merck Patent Gmbh | Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
| PL374269A1 (en) * | 2001-08-21 | 2005-10-03 | Chiron Corporation | Kgf polypeptide compositions |
| US7202066B2 (en) * | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
| GB0426394D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| JP5201992B2 (ja) * | 2004-12-15 | 2013-06-05 | バイオビトラム・アクテイエボラーグ（パブリツク） | ケラチノサイト増殖因子の治療用製剤 |
| US20060183712A1 (en) * | 2005-02-17 | 2006-08-17 | The Texas A&M University System | Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor |
| WO2007081447A2 (en) | 2005-11-22 | 2007-07-19 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
| GB0611405D0 (en) | 2006-06-09 | 2006-07-19 | Univ Belfast | FKBP-L: A novel inhibitor of angiogenesis |
| US20080119433A1 (en) * | 2006-07-06 | 2008-05-22 | Aaron Thomas Tabor | Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance |
| KR101021197B1 (ko) * | 2008-04-11 | 2011-03-11 | (주)케어젠 | 성장인자―미미킹 펩타이드 및 그의 용도 |
| EP2454368A4 (en) | 2009-07-17 | 2013-01-09 | Aaron Thomas Tabor | COMPOSITIONS AND METHOD FOR THE GENETIC MODIFICATION OF COSMETIC FUNCTION CELLS FOR IMPROVING THE COSMETIC APPEARANCE PICTURE |
| CA2928526A1 (en) | 2013-11-01 | 2015-05-07 | Spherium Biomed S.L. | Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents |
| CN117858717A (zh) | 2021-08-30 | 2024-04-09 | 联合化学实验室有限公司 | 用于治疗炎症性疾病的蛋白质组合物 |
| KR102691028B1 (ko) * | 2021-11-15 | 2024-08-05 | (주)피앤피바이오팜 | 안정성이 증가된 인간 각질세포 성장인자1 변이체 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990008771A1 (en) | 1989-01-31 | 1990-08-09 | Rubin Jeffrey S | Dna encoding a growth factor specific for epithelial cells |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US5965530A (en) | 1993-03-26 | 1999-10-12 | Amgen Inc. | Therapeutic uses of keratinocyte growth factor |
| WO1995001434A1 (en) | 1993-06-29 | 1995-01-12 | Chiron Corporation | A truncated keratinocyte growth factor (kgf) having increased biological activity |
| CN1168678A (zh) | 1994-10-13 | 1997-12-24 | 安姆根有限公司 | 用kgf治疗糖尿病的方法 |
| SI0785950T1 (en) | 1994-10-13 | 2003-08-31 | Amgen Inc. | Keratinocyte growth factor analogs |
-
1994
- 1994-04-28 WO PCT/US1994/004694 patent/WO1995001434A1/en active IP Right Grant
- 1994-04-28 PT PT94916597T patent/PT706563E/pt unknown
- 1994-04-28 DE DE1994634053 patent/DE122006000005I2/de active Active
- 1994-04-28 DE DE69434053T patent/DE69434053T2/de not_active Expired - Lifetime
- 1994-04-28 NZ NZ266622A patent/NZ266622A/en unknown
- 1994-04-28 AT AT94916597T patent/ATE278777T1/de active
- 1994-04-28 DK DK94916597T patent/DK0706563T3/da active
- 1994-04-28 HU HU9503857A patent/HUT73453A/hu unknown
- 1994-04-28 EP EP04023638A patent/EP1493812A3/en not_active Ceased
- 1994-04-28 ES ES94916597T patent/ES2227527T3/es not_active Expired - Lifetime
- 1994-04-28 PL PL94312257A patent/PL312257A1/xx unknown
- 1994-04-28 SK SK1532-95A patent/SK153295A3/sk unknown
- 1994-04-28 BR BR9407035A patent/BR9407035A/pt not_active Application Discontinuation
- 1994-04-28 CZ CZ953437A patent/CZ343795A3/cs unknown
- 1994-04-28 AU AU68208/94A patent/AU681405B2/en not_active Ceased
- 1994-04-28 CA CA002166278A patent/CA2166278A1/en not_active Abandoned
- 1994-04-28 CN CN94193193A patent/CN1129955A/zh active Pending
- 1994-04-28 JP JP50346495A patent/JP3570516B2/ja not_active Expired - Fee Related
- 1994-04-28 KR KR1019950705997A patent/KR960703433A/ko not_active Application Discontinuation
- 1994-04-28 EP EP94916597A patent/EP0706563B1/en not_active Expired - Lifetime
-
1995
- 1995-03-27 US US08/410,941 patent/US5677278A/en not_active Expired - Lifetime
- 1995-06-06 US US08/467,937 patent/US5863767A/en not_active Expired - Lifetime
- 1995-06-06 US US08/468,547 patent/US5843883A/en not_active Expired - Lifetime
- 1995-06-06 US US08/468,546 patent/US5773586A/en not_active Expired - Lifetime
- 1995-12-20 NO NO955189A patent/NO955189L/no unknown
- 1995-12-20 BG BG100236A patent/BG100236A/xx unknown
- 1995-12-22 FI FI956203A patent/FI956203A/fi unknown
-
1998
- 1998-05-08 US US09/074,950 patent/US6074848A/en not_active Expired - Lifetime
-
2000
- 2000-05-16 US US09/573,068 patent/US6677301B1/en not_active Expired - Fee Related
-
2004
- 2004-02-10 JP JP2004034289A patent/JP2004166709A/ja not_active Withdrawn
-
2005
- 2005-11-17 JP JP2005333438A patent/JP2006075173A/ja not_active Withdrawn
-
2006
- 2006-01-26 NL NL300217C patent/NL300217I2/nl unknown
- 2006-01-27 LU LU91215C patent/LU91215I2/en unknown
- 2006-01-31 FR FR06C0004C patent/FR06C0004I2/fr active Active
-
2007
- 2007-06-11 US US11/811,560 patent/US20090093400A1/en not_active Abandoned
-
2008
- 2008-11-26 JP JP2008301630A patent/JP4662569B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI956203A0 (fi) | Lisääntyneen biologisen aktiivisuuden omaava katkaistu keratinosyyttika sivutekijä (KGF) | |
| ITRM940820A0 (it) | "composizione per il controllo degli insetti nocivi" | |
| ATE133200T1 (de) | Modifiziertes, biologisch aktives protein | |
| ES2088860T3 (es) | Activador plasminogenico de tipo tisular humano modificado y su preparacion. | |
| DE69024104D1 (de) | Polypeptide und Polypeptidanaloge mit inhibitorischer Aktivität gegenüber menschlicher Elastase | |
| DE69126049D1 (de) | Vektoren und Zusammensetzungen zur Expression von Glykosilationsmutanten des menschlichen Proteins-C | |
| DE122007000030I1 (de) | Für menschliches Papillomavirus stamm 18 kodierende DNS | |
| PT90504A (pt) | Processo para a preparacao de alcoois peptidicos com actividade anticoagulante | |
| CA2066263A1 (en) | Tsh receptor | |
| HUT51647A (en) | Process for production of reduced non-glycolized recombined human il under 2 | |
| SE8801723D0 (sv) | Fibronectin binding protein as well as its preparation | |
| ATE145939T1 (de) | Mitogen für die glatte muskulatur und dessen kodierende dns | |
| IT1231764B (it) | Composizione poliuretanica con capacita' di assorbire umidita', particolarmente adatta per la fabbricazione di cuoio sintetico e simili, e procedimento per la sua produzione. | |
| EP0254272A3 (en) | The use of probucol for preventing and treating heart diseases | |
| EP0206329A3 (en) | Sprung floor | |
| DE3877015D1 (de) | Antikoerper enthaltende stabilisierte waesserige zusammensetzung. | |
| RU95114858A (ru) | Новый пептидный фрагмент, обладающий биологической активностью инсулина | |
| DE69635457D1 (de) | Deprenyl induziertes protein | |
| ATE290598T1 (de) | Neue staphylokinase derivate | |
| IT219518Z2 (it) | Leva di comando particolarmente per l'azionamento di gruppi valvolari | |
| TH22943A (th) | รีคอมบิแนนท์โปรตีนที่กำหนดเป็น dev-1 ที่มีประโยชน์สำหรับตรวจหา hiv ลำดับดีเอนเอที่ประมวลรหัสของโปรตีนและการวิเคราะห์ทางอิมมูนโดยใช้โปรตีนนี้ | |
| IT8720590A0 (it) | Composti ad attivita' nootropa. | |
| MX9604896A (es) | Mejoramientos en o relacionados a la resistencia de las plantas contra enfermedades. |